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Toxoplasmosis, which affects more than a billion people worldwide, is a common parasitic infection 
caused by the obligate intracellular parasite, Toxoplasma gondii. Current treatment strategies have several 
limitations, including unwanted side effects and poor efficacy. Therefore, newer therapies are needed for 
toxoplasmosis. Drug repurposing and screening of a vast array of natural and/or synthetic compounds is a 
viable option for antiparasitic drug discovery. In this study, we screened 62 compounds comprising natural 
products (NPs†) and FDA-approved (FDA) drugs, to identify the hit compounds that suppress the growth 
of T. gondii. To determine the parasite inhibitory potential of the compounds, host mammalian cells were 
infected with a transgenic T. gondii strain, and the viability of the parasite was evaluated by luminescence. 
Of the 62 compounds, tubericidin, sulfuretin, peruvoside, resveratrol, narasin and diacetoxyscirpenol of 
the natural product isolates, as well as bortezonib, 10-Hydroxycamtothecin, mebendazole, niflumic acid, 
clindamycin HCl, mecamylamine, chloroquine, mitomycin C, fenbendazole, daunorubicin, atropine, and 
cerivastatin of FDA molecules were identified as “hits” with ≥ 40 percent anti-parasite action. Additionally, 
mitomycin C, radicicol, naringenin, gitoxigenin, menadione, botulin, genistin, homobutein, and gelsemin 
HCl of the natural product isolates, as well as lomofungin, cyclocytidine, prazosin HCl, cerivastatin, 
camptothecin, flufenamic acid, atropine, daunorubicin, and fenbendazole of the FDA compounds exhibited 
cytotoxic activity, reducing the host viability by ≥ 30 percent. Our findings not only support the prospects 
of drug repurposing, but also indicate that screening a vast array of molecules may provide viable sources 
of alternative therapies for parasitic infection. 
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INTRODUCTION
Toxoplasmosis, which is caused by the obligate 
intracellular parasite Toxoplasma gondii [1-3], is a com-
mon parasitic infection affecting more than a billion 
people worldwide. The parasite exists in three forms, 
tachyzoites, bradyzoites, and sporozoites, found in defin-
itive and non-definitive hosts. However, only two forms, 
tachyzoites and bradyzoites of the parasite exist in hu-
man and non-definitive hosts. In healthy individuals, a 
T. gondii infection can occur without symptoms, but in 
immune-compromised or pregnant individuals, T. gondii 
infection often results in serious illness or death [4,5]. 
For example, T. gondii infection in HIV-AIDS patients 
is associated with encephalitis, and in pregnant women, 
numerous cases of miscarriages and fetal deformities 
have been linked with the Toxoplasma infection [4,5]. 
Infection of a mammalian host usually comes about by 
contact with the parasite, either by the consumption of the 
bradyzoite form in undercooked meat or from the sporo-
zoite form in felid feces, which can contaminate drinking 
water or occur elsewhere in the environment, such as on 
unwashed vegetables or in cat litter.
Currently, antimalarials, such as pyrimethamine, 
and/or antibiotics, such as clindamycin HCl, are among 
the therapies of choice for active toxoplasmosis [6]. 
However, poor tolerance and limited efficacy are major 
challenges of these therapeutic options. Additionally, 
the available treatments are not effective against latent 
infections. Thus, toxoplasmosis remains a growing health 
burden globally, necessitating the identification of newer 
therapies. Recent investigations have shown that both 
drug repurposing and screening a vast array of molecules 
for antiparasite potential are viable approaches to drug 
discovery [7-14]. Screening a vast array of chemical 
compounds, including the repurposing of already ap-
proved drugs, may allow the discovery of lead antipara-
sitic infection candidates in early drug development. For 
example, testing well-characterized drugs and other types 
of compounds, which are currently approved to treat 
other conditions, for potential off-label indications could 
not only allow the identification of lead targets but also 
boost efforts toward developing lead candidates. Indeed, 
emerging reports have identified several potent, new an-
tiparasitic agents by screening well-characterized drugs 
or compounds that inhibit specific pathways or processes 
[6,9,10]. In this study, we screened both natural product 
isolates and FDA-approved compounds, to identify those 
that possess suppressive action against the in vitro growth 
of T. gondii.
MATERIALS AND METHODS
Natural Product Isolates and FDA-approved Drugs
The natural products and FDA-approved compounds 
in stock solutions of DMSO were provided without 
charge from the Kanazawa University Cancer Institute, 
Japan. Pyrimethamine (Sigma Aldrich, St. Louis, MO, 
USA) was included in all the experiments as the reference 
drug.
Parasite
In this study, the transgenic T. gondii RH strain 2F 
(ATCC® 50839), which expresses β-galactosidase, was 
used, unless indicated otherwise. To sustain the parasite, 
T. gondii was repeatedly passaged in cultures of human 
foreskin fibroblast (HFF; ATCC®) monolayers in a me-
dium composed of Dulbecco’s modified Eagle medium 
(DMEM; Nissui, Tokyo, Japan), 1% L-glutamine (200 
mM Gibco, Fisher, UK), fetal calf serum (10% v/v; Gib-
co, Fisher, UK), and 1% penicillin and streptomycin (100 
U/mL Biowhittaker, UK). To obtain a purified suspension 
of T. gondii, the infected host cells were lysed, filtered, 
and washed several times with fresh culture medium, as 
described elsewhere [8].
Assay to Determine Parasite Growth Inhibition
An assay to determine whether the compounds affect 
parasite growth was performed as described elsewhere 
[8]. The multiplicity of infection (MOI) was 1:5 (parasite/
host cell ratio). In brief, the test compounds were recon-
stituted in culture medium at five concentrations (between 
0 – 1.5 µg/mL), and incubated with newly purified para-
sites in monolayers of HFF cells grown in 96-well optical 
bottom plates (Nunc; Fisher Scientific, Pittsburgh, USA). 
The cells treated with medium only served as the negative 
drug control, while the medium-only well was used for 
background signal correction. To validate the assay, pyri-
methamine was included as a positive drug control. After 
a 72-h incubation at 37oC in a 5% CO
2
 atmosphere, the 
parasite viability was determined by luminescence using 
a Beta-Glo assay kit (Promega, Madison, USA). Three 
independent biological experiments were performed, and 
each of which had three tests.
Assay to Determine Host Cell Viability
The host cell viability assay was performed as previ-
ously reported elsewhere [8]. Cultures of HFF cells were 
grown to confluence in medium as described above in 
an atmosphere of 5% CO
2 
and 37oC. The confluent cells 
were sub-cultured and seeded in 96-well plates (Nunc; 
Fisher Scientific, Pittsburgh, USA) at a density of 1 × 105 
cells per well, followed by 72-h incubation at 37oC and 
5% CO
2
 atmosphere. Subsequently, the test compounds 
were added at five concentrations (between 0 – 3 µg/mL) 
to the culture medium. The negative drug control con-
tained only the culture medium, whereas the medium-on-
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ly well was used for background noise correction. To 
validate the assay, a positive control drug, staurosporine 
(1 µM final concentration) was used [15]. After a 72-h 
incubation under the tissue culture conditions indicated 
above, the viability of cells was determined by colorimet-
ric measurement (CellTitre-Aqueous One kit, Promega, 
Madison, USA) at 490 nm on a microplate reader (MTP 
500; Corona Electric, Hitachinaka, Japan). Three inde-
Figure 1. Growth inhibition of Toxoplasma gondii RH-2F strain by natural product isolates at a concentration of 1 μg/
mL. DMSO (0.5%) control was calculated as 0% inhibition, and 200 μg/mL pyrimethamine positive drug control was 
calculated as 100% growth inhibition. Data are presented as mean values of three replicates ± standard errors of the 
mean.
Figure 2. Growth inhibition of Toxoplasma gondii RH-2F strain by FDA-approved compounds at a concentration of 
1.5 μg/mL. DMSO (0.5%) control was calculated as 0% inhibition, and 200 μg/mL pyrimethamine positive drug control 
was calculated as 100% growth inhibition. Data are presented as mean values of three replicates ± standard errors of 
the mean.
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host cell viability or inhibited Toxoplasma growth by 50 
percent.
Molecular and In Silico Studies: ADME (Absorption, 
Distribution, Metabolism, Excretion), Bioactivity, 
and Toxicity
pendent biological experiments were performed, each of 
which had three tests. Meanwhile, selectivity index (SI) 
for the compounds was estimated so at identify promising 
anti-Toxoplasma compounds with low or no toxicity to 
host cells. The SI is the ratio of the IC50 concentration in 
host cells (HFF) to that in parasite (T. gondii). The IC50 
is the concentration of the compound that either reduces 
Figure 3. Viability of host cell (human foreskin fibroblast) by natural product isolates at 2 μg/mL. DMSO (0.5%) con-
trol was calculated as 100% cell viability. Data are presented as mean values of three replicates ± standard errors of 
the mean.
Figure 4. Viability of host cell (human foreskin fibroblast) by FDA-approved compounds at 3 μg/mL. DMSO (0.5%) 
control was calculated as 100% cell viability. Data are presented as mean values of three replicates ± standard errors 
of the mean.
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Compounds aInhibition of Toxoplasma 
gondii (%)
bHost (HFF) cell 
viability (%)
Tubericidin 78.45±1.23 ≥40 % anti-T. gondii activity 81.17±5.20
Sulfuretine 57.31±2.58 ≥40 % anti-T. gondii activity 110.69±6.46
Peruvoside 52.09±0.93 ≥40 % anti-T. gondii activity 40.96±1.62
Resveratrol 51.60±1.66 ≥40 % anti-T. gondii activity 110.46±5.80
Narasin 45.56±0.43 ≥40 % anti-T. gondii activity 79.09±3.17
Diacetoxyscirpenol 44.67±2.98 ≥40 % anti-T. gondii activity 82.87±1.85
Cephaeline.HBr 38.92±0.14 90.10±9.77
Rhapontin 37.46±2.09 91.32±4.65
Lasalocid A 37.10±2.64 105.63±6.02
Shikonin 36.05±3.10 104.52±4.66
Arbutin 35.64±1.22 97.26±5.18
Piperine 34.16±1.14 86.68±3.79
Mitomycin C 30.83±1.53 4.44±0.57
Hesperitine 30.69±1.17 90.92±8.80
Strophantidin 30.23±1.41 108.97±4.43
Gitoxigenin 29.57±1.59 20.25±0.94
5,6-Dehydrokawain 24.52±2.59 107.45±5.59
Butein 23.79±0.93 89.44±6.59
Amphotericin B 23.09±1.21 79.21±6.35
Stachydrine.HCl 22.39±2.68 100.35±5.53
Naringenin 22.20±0.73 27.28±3.70
Homobutein 19.48±1.45 64.14±2.07
Radicicol 18.68±1.86 19.12±1.13
Lavendustin A 15.78±0.92 91.50±7.90
Gelsemine.HCl 14.10±0.42 46.17±3.58
Genistin 12.55±1.22 7.52±0.37
Aloe-emodine 10.39±0.18 106.75±3.82
Betulin 8.87±0.66 35.30±2.08
Ochratoxin A 6.59±0.84 107.83±4.68
Menadione 5.76±0.18 18.21±1.53
Syringetine-3-glucoside 4.78±0.53 79.49±12.26
Andrographolide 2.60±0.86 94.12±6.23
Capsiacin -2.14±1.30 101.92±6.19
Eriodictyol -4.93±1.12 110.38±2.89
Neohesperidin -6.24±1.71 105.79±7.21
Curcumin -8.89±0.28 90.31±5.66
Table 1. Inhibition of Toxoplasma gondii growth and host cell viability by natural product isolates.
aParasite growth inhibition values from preliminary screening with RH-2F at 1 μg/mL concentration. DMSO (0.5%) control was cal-
culated as 0% inhibition, and 200 μg/mL pyrimethamine control was calculated as 100% growth inhibition. bHost cell viability values 
from preliminary screening with HFF cells at 2 μg/mL concentration. DMSO control was calculated as 100% cell viability.
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Table 2. Estimate of selectivity index for natural product isolates.
*ND – Not determined.
Compounds IC50 Toxoplasma gondii
(µg/mL)
IC50 HFF cells
(µg/mL)
Selectivity Index
(SI)
Rhapontin 1.22 20.05 16.38 SI >1
Homobutein 4.43 68.28 15.41 SI >1
Sulfuretine 0.68 8.20 12.10 SI >1
Arbutin 17.20 84.23 4.90 SI >1
Butein 2.12 7.92 3.74 SI >1
Naringenin 3.03 9.20 3.03 SI >1
Narasin 0.74 2.09 2.84 SI >1
Stachydrine.HCl 4.40 10.41 2.36 SI >1
Shikonin 3.96 5.81 1.47 SI >1
Hesperitine 13.66 12.42 0.91
Lasalocid A 1.61 1.46 0.90
Ochratoxin A 11.33 9.63 0.85
Radicicol 4.90 2.58 0.53
Cephaeline.HBr 0.95 0.45 0.47
Menadione 44.70 17.93 0.40
Peruvoside 0.37 0.11 0.30
Sulfadiazine 185.20 53.35 0.29
Mitomycin C 1.87 0.44 0.24
Gitoxigenin 2.59 0.62 0.24
Pyrimethamine 205.60 42.16 0.21
Strophantidin 1.30 0.19 0.15
Diacetoxyscirpenol 0.62 0.05 0.08
Tubericidin 0.46 0.02 0.04
Capsiacin ND 9.69 ND
Curcumin ND ND ND
Resveratrol 1.03 ND ND
Genistin 5.46 ND ND
Eriodictyol ND ND ND
Andrographolide 388.10 ND ND
Syringetine-3-glucoside 16.64 ND ND
Piperine 1.71 ND ND
Aloe-emodine 8.14 ND ND
Neohesperidin ND ND ND
5,6-Dehydrokawain 4.22 ND ND
Betulin 224.40 ND ND
Lavendustin A 37.45 ND ND
Gelsemine.HCl 89.29 ND ND
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modulation, GPCR ligand, kinase inhibition, nuclear 
receptor interaction, protease inhibition, and enzyme in-
hibition activities, was also determined [16].
The in silico toxicity was determined using ProTox-II 
[17,18], a web-based computational modeling tool com-
prising about 33 models that can predict various toxicity 
endpoints, which include hepatotoxicity, cytotoxicity, 
carcinogenicity, mutagenicity, immunotoxicity, adverse 
outcomes pathways, toxicity targets, and acute toxicity.
Toxicity Potential and Classes
For the in silico toxicity evaluation, the toxic doses 
were given as LD50 values in mg/kg body weight. The 
The modeling for physicochemical, pharmacokinet-
ic, and bioactivity properties of some selected compounds 
were performed using the Molinspiration Cheminformat-
ics server (http://www.molinspiration.com). Compounds 
were randomly selected from among those with SI> 1. 
The SMILE formats of the compounds (with their corre-
sponding identities) were obtained from https://pubchem.
ncbi.nlm.nih.gov/. Features, including partition coeffi-
cient, total polar surface area, molecular weight, molecu-
lar volume, number of hydrogen bond acceptors/donors, 
mean number of rotatable bonds, and degree of violation 
of Lipinski’s rule, were obtained following the reported 
standard procedure. The bioactivity score (based on Lip-
inski’s “Rule of five”), which evaluates the ion channel 
Table 3. Inhibition of Toxoplasma gondii growth and host cell viability by FDA-approved chemical 
compounds.
aParasite growth inhibition values from preliminary screening with RH-2F at 1.5 μg/mL concentration. DMSO (0.5%) control was cal-
culated as 0% inhibition, and 200 μg/mL pyrimethamine control was calculated as 100% growth inhibition. bHost cell viability values 
from preliminary screening with HFF cells at 3 μg/mL concentration. DMSO control was calculated as 100% cell viability.
Compounds aInhibition of 
Toxoplasma gondii (%)
bHost (HFF) cell 
viability (%)
Bortezomib 60.13±1.78 ≥40 % anti-T. gondii activity 86.64±6.65
10-Hydroxycamptothecin 58.16±2.01 ≥40 % anti-T. gondii activity 100.55±1.58
Mebendazol 55.14±0.98 ≥40 % anti-T. gondii activity 75.86±3.31
Niflumic acid 52.31±1.83 ≥40 % anti-T. gondii activity 99.96±4.02
Clindamycin HCl 47.39±1.31 ≥40 % anti-T. gondii activity 105.77±2.43
Mecamylamine 47.06±2.02 ≥40 % anti-T. gondii activity 87.76±4.92
Chloroquine 45.14±2.62 ≥40 % anti-T. gondii activity 82.54±4.10
Mitomycin C 45.06±1.87 ≥40 % anti-T. gondii activity 103.37±3.84
Fenbendazole 41.62±1.70 ≥40 % anti-T. gondii activity 21.82±1.24
Daunorubicin 41.60±1.19 ≥40 % anti-T. gondii activity 62.27±0.72
Atropine 41.10±1.07 ≥40 % anti-T. gondii activity 44.73±1.30
Cerivastatin 41.07±1.44 ≥40 % anti-T. gondii activity 24.12±2.47
Camptothecin 37.38±1.32 27.68±2.54
Flufenamic acid 29.21±0.16 28.01±2.95
Prazosin.HCl 28.91±1.82 4.70±1.05
Sulfasalazine 27.93±1.74 104.16±5.22
Azaperone 27.24±2.00 93.09±3.22
Aclarubicin 25.13±0.42 94.05±4.80
Neostigmine 24.01±1.05 75.51±13.61
Anethole-trithione 21.98±1.00 86.65±4.93
Diflunisal 21.13±1.69 87.93±8.43
Lincomycin 21.04±1.32 113.67±8.48
Lomofungin 18.43±1.92 51.65±6.83
Cyclocytidine 16.93±1.05 51.24±2.09
Cytarabine 14.59±1.18 72.36±9.24
Amifostine 12.94±1.65 102.99±5.23
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Statistical Analysis
A one-way ANOVA was used to analyze the data 
utilizing GraphPad Software (San Diego, CA, USA). 
The results are presented as the mean of three replicates 
± standard error of mean (SEM). The Dunnet post-hoc 
test was used to compare the groups, and the mean val-
ues were considered significant at p < .05. A non-linear 
regression analysis (curve fit) was used to estimate the 
concentration that caused inhibition of T. gondii growth 
or cellular toxicity by 50% (IC50).
model takes LD50 as the median lethal dose, indicating 
the dose at which 50 % of the test subjects die upon ex-
posure to the test compound. The toxicity classes were 
defined according to the Globally Harmonized System of 
Classification and Labeling of Chemicals (GHS). Within 
the group of substances that showed acute oral toxicity, 
the GHS classification, class 1 is designated as fatal if 
swallowed at LD50≤ 5; class 2: fatal if swallowed at 5 < 
LD50≤ 50; class 3: toxic if swallowed at 50 < LD50≤ 300; 
class 4 harmful if swallowed at 300 < LD50≤ 2000; class 
5: may be harmful if swallowed at 2000 < LD50≤ 5000, 
and class 6: non-toxic at LD50> 5000 [18,19].
Table 4. Estimate of selectivity index for FDA-approved chemical compounds.
Compounds IC50 Toxoplasma 
gondii (µg/mL)
IC50 HFF cells
(µg/mL)
Selectivity Index 
(SI)
Atropine 2.20 61.35 27.85 SI >1
Niflumic acid 1.07 26.06 24.47 SI >1
Clindamycin HCl 1.59 25.79 16.22 SI >1
Azaperone 6.40 82.00 12.82 SI >1
Chloroquine 1.97 17.54 8.90 SI >1
Mecamylamine 2.65 21.30 8.04 SI >1
Mebendazol 2.05 2.03 0.99
Lomofungin 31.64 18.02 0.57
10-Hydroxycamptothecin 1.50 0.79 0.53
Fenbendazole 5.42 2.69 0.50
Camptothecin 4.48 1.77 0.39
Mitomycin C 2.47 0.95 0.38
Sulfadiazine 185.20 53.35 0.29
Pyrimethamine 205.60 42.16 0.21
Cerivastatin 3.29 0.60 0.18
Bortezomib 1.82 0.12 0.07
Daunorubicin 6.39 0.35 0.05
Aclarubicin 110.70 3.52 0.03
Lincomycin 9.39 ND ND
Flufenamic acid 4.32 ND ND
Prazosin.HCl 5.87 ND ND
Neostigmine 17.11 ND ND
Anethole-trithione ND ND ND
Amifostine ND 59.81 ND
Cyclocytidine ND 27.52 ND
Cytarabine ND 42.01 ND
Diflunisal 34.38 ND ND
Sulfasalazine 4.88 ND ND
*ND – Not determined.
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proved compounds inhibited (p < .05) parasite growth 
by ≥ 40 percent (Figures 1 and 2). Meanwhile, determi-
nation of host cell viability in the presence of the same 
compounds showed that a total of 19 compounds repre-
senting, 27.77% and 34.62%, respectively, of the natural 
product isolates and FDA-approved drugs were cytotoxic 
(p < .05), causing a reduction in host cell viability by ≥ 
30 percent (Figures 3 and 4). Meanwhile, ≥ 65 percent 
of the total compounds from both the natural product 
isolates and the FDA-approved drugs, showed neither 
RESULTS
In this study, we screened a series of chemical en-
tities comprising both natural product isolates (36) and 
FDA-approved drugs (26), to identify those with sup-
pressive action or blocking capacity against the in vitro 
growth of T. gondii. Of the 62 compounds evaluated for 
dose-response antiparasite activity, the results showed 
that 18 compounds representing, 16.17% and 46.15%, 
respectively, of the natural product isolates and FDA-ap-
Figure 5. Chemical structures of hit compounds from the natural product isolates.
Figure 6. Chemical structures of hit compounds from the FDA-approved drugs.
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gondii potential (p < .05), but poor selectivity toward the 
parasite versus the host cells (Tables 3 and 4). Togeth-
er, the findings suggest general cellular toxicity of these 
compounds. To validate our assay, pyrimethamine was 
included as a reference drug and, as expected, this drug 
blocked parasite growth.
Additionally, a few of the compounds that blocked 
the in vitro growth of T. gondii, also exhibited multi-
ple-fold specificities (selectivity index (SI) ≥ 3) toward 
antiparasite activity nor any detectable host cytotoxicity. 
Furthermore, some of the natural compounds, including 
tubericidin, peruvoside, narasin, and diacetoxyscirpenol, 
that strongly blocked the in vitro growth of T. gondii at 
sub-microgram doses, lacked antiparasite specificity (p < 
.05), as these compounds were also were cytotoxic to the 
host cells at the same doses (Tables 1 and 2). Similarly, 
some of the FDA-approved drugs including 10-hydroxy-
camptothecin and bortezomib showed excellent anti-T. 
Table 5. ADME properties of the selected compounds/drugs.
miLogP - partition coefficient; TPSA - total polar surface area; MW - molecular weight; nON - number of hydrogen bond acceptors; 
nOHNH - number of hydrogen bond donors; noV - number of violations; nrotb - number of rotatable bonds; MV - molecular volume.
Compound or Drug 
PubChem ID
MiLogP TPSA 
(Å2)
MW
(g/mol)
nON nOHNH NoV nRotB MV
(A3)
Clindamycin hydrochloride 2.06 102.25 424.99 7 4 0 7 384.72
Mecamylamine 2.96 12.03 167.30 1 1 0 1 186.67
Chloroquine 5.00 28.16 319.88 3 1 1 8 313.12
Azaperone 2.88 36.44 327.40 4 0 0 6 307.55
Atropine 1.77 49.77 289.38 4 1 0 5 279.01
Niflumic acid 3.42 62.22 282.22 4 2 0 4 222.00
Sulfuretin 1.76 90.89 270.24 5 3 0 1 224.05
Homobutein 2.59 86.99 286.28 5 3 0 4 251.45
Arbutin -0.81 119.61 272.25 7 5 0 3 232.20
Rhapontin 1.02 149.07 420.41 9 6 1 6 364.59
Pyrimethamine 2.84 77.83 248.72 4 4 0 2 216.62
Sulfadiazine -0.04 97.98 250.28 6 3 0 3 202.26
Figure 7. Distribution of active natural product compounds based on (A) bioactivity, (B) functional groups, and (C) 
treatment indications for FDA-approved drugs.
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rhapontin and arbutin are glycosides and piperine is an 
alkaloid. Interestingly, our study is the first report show-
ing a mild suppressive action of homobutein, butein, 
rhapontin, and arbutin against the in vitro growth of T. 
gondii. However, homobutein has been reported as hav-
ing antimalarial activity [22,23] and anti-inflammatory, 
antioxidant, and antitumor potential [24-26]. In separate 
investigations, the anti-inflammatory, antioxidant, and 
antibacterial potential of rhapontin and arbutin have each 
been documented [27-29]. Additionally, piperine has 
been implicated as having anti-inflammatory properties 
[30] as well as anti-T. gondii activity [31].
Furthermore, the ADME properties and drug like-
ness (Lipinski’s rule of five) of the standard anti-Toxo-
plasma drugs were compared with those of a select few of 
the FDA-approved drugs and natural product compounds 
that showed SI>1 (Tables 2, 4, and 5). While only chlo-
roquine and rhapontin showed one violation each of the 
Lipinski’s rule, mecamylamine had the lowest total polar 
surface area (12.03 Å2) and molecular volume (186.67 A3) 
as well as molecular weight (167.30 g/mol). The majority 
of the compounds had molecular weights and molecular 
volumes below 500. While all the compounds showed 
prospects for application as anti-Toxoplama agents, me-
camylamine (an FDA-approved drug) and sulfuretin (a 
natural product) seemed to show greater potential based 
on their ADME properties.
The result of the bioactivity and drug-likeness mea-
sures are presented in Table 6. Comparatively, chloroquine 
the parasite versus the host cells with EC50 ranging in the 
sub-microgram concentration. A selectivity index ≥ 1 is 
considered promising for early drug development against 
parasitic infection [20]. Some of the natural product iso-
lates with promising antiparasite specificities included 
sulfuretin, resveratrol, and narasin (Figure 5), while those 
of the FDA-approved drugs were mecamylamine, atro-
pine, niflumic acid, clindamycin HCl, and chloroquine 
(Figure 6). Taken together, the findings indicate not only 
specific antiparasite action by these compounds but also 
that the antiparasite action of these compounds was not a 
result of toxicity to the host cells. Given these results, the 
hit compounds could be considered as early drug devel-
opment candidates for toxoplasmosis therapy.
Furthermore, of the identified antiparasitic com-
pounds from both the natural product isolates and the 
FDA-approved drugs, the majority were effective and/
or used against inflammatory related conditions (Figure 
7a-c). Similarly, two of the effective natural anti-T. gondii 
isolates were phenolics. Considered together, the findings 
reinforce existing investigations that demonstrated that 
drugs and/or compounds used in inflammatory therapy 
blocked parasite growth in vitro [6,10,21].
Moreover, a few of the natural product isolates in 
this study showed mild activity against the growth of 
T. gondii and the same compounds also demonstrated 
a promising selectivity index (Tables 1 and 2). Among 
these are butein, homobutein, rhapontin, arbutin, and 
piperine. While butein and homobutein are flavonoids, 
Table 6. In silico bioactivities for the selected compounds/drugs.
GPCR ligand, ICM - ion channel modulation; KI - kinase inhibition; NRL - nuclear receptor ligand; PI - protease inhibition; EI - en-
zyme inhibition
Compound or Drug Name PubChem 
CID
GPCR 
ligand
ICM KI NRL PI EI
FDA Approved drugs
Clindamycin hydrochloride 16051951 0.33 -0.11 -0.54 -0.27 0.47 0.23
Mecamylamine 4032 -0.70 0.03 -1.47 -1.18 -0.80 -0.66
Chloroquine 2719 0.32 0.32 0.38 -0.19 0.05 0.11
Azaperone 15443 0.26 0.09 0.15 -0.17 -0.02 0.12
Atropine 174174 0.44 0.26 -0.09 -0.06 0.13 0.21
Niflumic acid 4488 0.04 0.04 0.29 -0.03 -0.11 0.11
Natural Products
Sulfuretin 5281295 -1.18 -1.26 -0.52 -0.56 -1.21 0.00
Homobutein 6438092 -0.10 -0.19 -0.24 0.02 -0.31 0.06
Arbutin 440936 0.05 0.12 -0.13 0.04 -0.09 0.46
Rhapontin 637213 0.10 0.02 0.01 0.14 -0.02 0.30
Standard anti-toxoplasma drugs
Pyrimethamine 4993 0.31 0.07 0.38 -0.61 -0.14 0.66
Sulfadiazine 5215 -0.29 -0.39 -0.14 -0.92 -0.47 -0.01
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LD50≤ 5000) indicating potential relative safety on usage. 
Clindamycin hydrochloride, chloroquine, azaperone, ho-
mobutein, and rhapontin showed mild immunotoxic po-
tential, and sulfuretin and sulfadiazine exhibited potential 
carcinogenicity. No specific toxicity effect was reported 
for mecamylamine, atropine, arbutin, or the standard, 
pyrimethamine in the model used. Like the standard (py-
rimethamine), all the natural products showed average 
potential toxicity to prostaglandin synthase 1 and amine 
oxidase A.
exhibited the highest potentials, in terms of its GPCR li-
gand, ion channel modulation, and kinase inhibition. In 
the natural products group, arbutin and rhapontin showed 
parameters comparable with the standard drug, pyrimeth-
amine. All the selected FDA-approved drugs and natural 
products exhibited potential for further in vivo evalua-
tion. The result of the in silico toxicity evaluation (Table 
7) revealed that all the tested drugs and compounds had 
toxicities in classes 3 and 5. Interestingly, only homobu-
tein and arbutin (natural product compounds) belong to 
toxicity class 5 (may be harmful if swallowed (2000< 
Carcino - carcinogenicity; Mutag - mutagenicity; Immuno- immunotoxicity; MMP- mitochondrial membrane potential; TSRP - Tox21-
stress response pathways; TEP - toxicity end points; ND - none detected; NA - not applicable; PGH - prostaglandin G/H
Table 7. In silico toxicity model result.
Compound
or Drug Name
Potential 
Effects
Classification Probability Possible 
toxicity 
targets
Average 
Pharmacophore 
Fit (%)
Predicted 
LD50 (mg/
kg)
Predicted 
Toxicity 
Class
FDA Approved drugs
Clindamycin 
hydrochloride
Immuno TEP 0.93 Amine 
Oxidase A
70.29 1095 4
Mecamylamine ND NA NA Dopamine 
receptor 
D3
0 90 3
Chloroquine Immuno
Mutag
TEP
TEP
0.99
0.94
ND NA 311 4
Azaperone Immuno TEP 0.54 Histamine 
Receptor 
H1
56.12 63 3
Atropine ND NA NA PGH 
Synthase 
1
48.05 75 3
Niflumic acid MMP TSRP 1.0 Amine 
Oxidase A
58.28 250 3
Natural Products
Sulfuretin Carcino
Immuno
MMP
TEP
TEP
TSRP
0.71
0.85
0.76
PGH 
Synthase 
1
50.32 500 4
Homobutein Immuno
MMP
TEP
TSRP
0.99
0.93
Amine 
Oxidase A
63.3 2100 5
Arbutin ND NA NA PGH 
Synthase 
1
66.5  2420 5
Rhapontin Immuno Toxicity end 
points
0.99 PGH 
Synthase 
1
0 1380 4
Standard anti-Toxoplasma drugs
Pyrimethamine ND NA NA Amine 
Oxidase A
64.07 92 3
Sulfadiazine Carcino Toxicity end 
points
0.76 PGH 
Synthase 
1
58.4 1500 4
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hit compounds (resveratrol and sulfuretin) from the natu-
ral product isolates are phenolics. Interestingly, our study 
is the first report to show a suppressive action of sulfure-
tin against the in vitro growth of T. gondii. Nevertheless, 
some of the hit compounds have been reported as having 
other bioactive properties. For example, resveratrol has 
been implicated as having anti-inflammatory properties 
[34] as well as anti-T. gondii activity [32]. Also, the an-
ti-inflammatory and antiparasitic actions of narasin have 
been previously documented [35]. It is worth noting that 
the majority of the hit compounds among the natural 
product isolates in this study have anti-inflammatory 
properties. This is consistent with our findings reported 
elsewhere [10], which revealed not only that the natural 
compounds active against T. gondii are mostly phenolics 
but also that the same compounds have anti-inflammatory 
activity. This same study also revealed that ≥ 75 percent 
of the FDA-approved drugs with activity against T. gon-
dii are therapeutic options for inflammatory-related con-
ditions. Given these findings, it is plausible to rationalize 
that the hit compounds identified in the study might have 
somewhat similar antiparasite mechanisms. Moreover, 
in the present study, the fact that a majority of the hit 
compounds possess anti-inflammatory potential may in-
dicate a way to identify new targets that could be further 
explored for development of more effective therapeutic 
options for toxoplasmosis. Taken together, the findings in 
this study not only support our earlier report [10] but also 
are consistent with those from other studies [6,21] that 
showed that drugs with anti-inflammatory indications 
suppressed the in vitro growth of T. gondii. Additionally, 
the in silico model supported the prospects of the iden-
tified anti-Toxoplasma-active compounds from both the 
FDA-approved and natural products for early drug dis-
covery against toxoplasmosis.
In conclusion, our study identified new chemical 
compounds from a group of natural product isolates and 
FDA-approved drugs that suppressed the in vitro growth 
of T. gondii. The findings are not only new and promising 
but also further reinforce the concept of screening a vast 
array of chemical entities, including drug repurposing, as 
a logical option in early drug development efforts for par-
asitic infections. Ongoing investigations aim to evaluate 
these compounds for in vivo efficacy against acute and 
latent toxoplasmosis in a mouse model.
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DISCUSSION
The screening of a vast array of chemical entities, 
including drug repurposing, is considered reasonable for 
identifying new therapeutic targets for the treatment of 
parasitic infection. For example, drug repurposing, in 
which well-characterized drugs and other types of chem-
ical entities are tested for potential off-label indications, 
can not only identify lead targets but can also be useful 
for drug development for parasitic infections [7].
In this study, we screened 62 chemical entities, to 
identify those that suppress the growth of T. gondii. Alto-
gether, a total of eight compounds from both the natural 
product isolates and the FDA-approved drugs showed an-
tiparasitic activity at sub-microgram doses. Additionally, 
some of these same compounds demonstrated promising 
selectivity with a selectivity index (SI) of a ≥3-fold ac-
tivity against the parasite versus the host cells. Together, 
these findings not only underscore the specific antipara-
site action shown by the compounds but also indicate that 
these compounds may be viable prospects in early drug 
development for toxoplasmosis. In comparison, pyri-
methamine, which is one of the current treatment options 
for toxoplasmosis, exhibited a ≤1-fold activity against the 
parasite versus the host cell.
Furthermore, most of the “hit” compounds (com-
pounds that blocked parasite growth with promising SIs) 
among the FDA-approved drugs had not been reported 
as having anti-T. gondii activity; the exceptions were 
clindamycin HCl and chloroquine. Respectively, clinda-
mycin HCl and chloroquine are therapeutic options for 
toxoplasmosis and malaria. Interestingly, the causative 
agents, T. gondii and Plasmodium spp. for toxoplasmosis 
and malaria, respectively, are intracellular apicomplex-
ans. This may indicate that most of the FDA-approved 
drugs that blocked T. gondii growth in the present study 
have similar clinical indications. For example, two of the 
hit compounds, mecamylamine and atropine, are used as 
therapeutic options for cardiac-related conditions, where-
as niflumic acid is used to treat inflammatory conditions. 
Previously, we showed that FDA-approved drugs used as 
anti-inflammatory therapies potently suppressed the in 
vitro growth of T. gondii [10]. Taken together, these find-
ings may underscore the prospects of anti-inflammatory 
agents as a source of alternative anti-T. gondii therapy. 
However, while the FDA-approved compounds are most-
ly well-characterized, their mechanisms of action against 
the growth of T. gondii are yet to be revealed and thus 
warrant further studies.
Among the hits from the natural product isolates, 
resveratrol has been previously reported as having anti-T. 
gondii properties [32], while narasin, a derivative of sa-
linomycin (an ionophoric anticoccidial compound), is a 
known antiprotozoan agent [33]. Additionally, two of the 
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